HealthEquity Inc. (HQY) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, HQY scores 78 out of 100, grading B+ under the verdict "Roarable Buy — Very Good Cash & Smart-Money Inflow." The Fundamental Cash Engine pillar scores 16 out of 20, supported by ROIC of 9.3% and an FCF yield of 5.43%; for an investor, this indicates the business converts capital into cash at a reasonable rate, though the 9.3% ROIC is moderate rather than exceptional. The Whale 13F Flow pillar scores 16 out of 20, reflecting institutional accumulation and options positioning as described in the RQD source; the underlying holder records are not provided in this dataset, so the pillar cannot be traced to specific filings here. The Insider Conviction pillar scores 12 out of 20, the lowest of the five, based on SEC Form 4 and Congressional PTR cluster flow; this is the weakest signal in the rating and suggests insider activity provides less confirmation than the other pillars. The Macro Regime Fit pillar scores 16 out of 20, with a beta of 0.96 indicating market-like volatility sensitivity. The Forensic Balance Sheet pillar scores 18 out of 20, the strongest pillar, citing an Altman Z of 4.86, a Piotroski F of 9/9, and Debt/Equity of 0.45. For a prospective investor, the upside case rests on cash generation and balance sheet strength; the valuation tradeoff is significant, since per the market data the stock trades at a trailing P/E of 39 and EV/EBITDA of 27.8, which means the market is pricing in substantial future growth and the rating does not itself establish that the price is justified.

HealthEquity Inc. is a NASDAQ-listed company classified under the Consumer Discretionary sector and Business Services industry, per the profile. Not available in source data for detailed product lines, customer base, or revenue mechanics. Per the market data, the company reports a gross margin of 69.5%, an operating margin of 24.6%, and a net margin of 16.4%, which indicate a high-margin revenue model, though the specific sources of that revenue are not described in the source data.

Per the SEC financials, revenue rose from $999.6M in FY 2023 to $1313.4M in FY 2025, net income rose from $55.7M to $215.2M, and debt declined from $1079.0M to $957.4M over the same span. Per the market data, the net margin is 16.4% and the operating margin is 24.6%. Per the Roarable RQD rating, the Altman Z-Score is 4.86 and the Piotroski F-Score is 9/9, and Debt/Equity is 0.45, with ROIC at 9.3%. The source data does not provide a balance sheet equity figure, so the Debt/Equity ratio cannot be independently verified from the filings provided.

Six news items are provided, all tagged to HQY. One item, a Yahoo Finance article titled "Is HealthEquity (HQY) a Solid Growth Stock? 3 Reasons to Think "Yes"," is flagged GREEN as a CATALYST. Five items are flagged YELLOW as MARKET WIRE: a TradingView estimates page, a Globe and Mail report on a Chief Commercial Officer leadership change, a Simply Wall St piece on how leadership changes have affected the investment story, a Yahoo! Finance Canada article on reasons to hold the stock, and a MarketBeat item noting a "Moderate Buy" rating from Wall Street analysts. The leadership change is the one item in this set that identifies a specific company event; the remaining headlines are generic market commentary whose summaries contain no substantive detail beyond general coverage language. Per the Butterfly Supply-Chain Graph, the supply_chain value is NONE, with no butterfly links and no proprietary signals recorded.

Analyst data is recorded as NONE in the source data, so consensus ratings and price targets are not available in source data. A MarketBeat headline reports a "Moderate Buy" rating by Wall Street analysts, but no underlying analyst count, targets, or breakdown is provided. Holder data is recorded as NONE, so no SEC Form 4 insider trades, 13F institutional holdings, or Congressional trades are available in source data beyond the aggregate pillar scores cited in the Roarable RQD rating.

• What specific revenue streams and customer segments drive the reported $1313.4M in FY 2025 revenue, and how much is recurring?
• What is the identity, size, and direction of the institutional holders and insider transactions underlying the Whale 13F Flow and Insider Conviction pillar scores?
• What is the analyst consensus rating count, price target range, and estimate revisions behind the "Moderate Buy" headline?
• What is the FY 2025 EPS and the total shareholder equity figure used to derive Debt/Equity of 0.45?
• What is the nature and scope of the Chief Commercial Officer leadership change, and does it affect the company's commercial strategy?